Glycine E640 is a white crystalline powder with a sweet taste. It is often used as a flavoring or a sweetener in combination with DL-alanine or Citric acid. Glycine is used in alcoholic beverages, peanut jams, and edible salt and vinegar. Though it’s considered safe, some are convinced it has potentially dangerous health effects.
What Is Glycine E640?
Glycine E640 is a white crystalline powder that is odorless and has a peculiar sweetness. Food grade Glycine E640 is mainly used as a nutritional supplement and food additive. It is also used in alcoholic beverages as an acid corrector or buffer for the composition of wine and soft beverage. Glycine E640 is used as an additive for the making of salted vegetables and sweet jams, sauces, vinegar and fruit juice. This product functions as a stabilizer for cream cheese, margarine, fast cooked noodles, white flour and pig lard.
Possible Side Effects of Glycine E640
Glycine E640 is generally considered a safe ingredient. The side effects may: nausea, vomiting, upper digestive tract discomfort, and mild drowsiness. However, potentially serious side effects of glycine can also occur. Contact your healthcare provider if you have symptoms of schizophrenia that are getting worse or develop signs of an allergic reaction while taking glycine supplements.
GRAS Affirmation: Yes
Generally recognized as safe (GRAS) is an American Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements. Glycine E640 is considered safe by FDA.
Suggested Dosage
NA.
Special Populations Precaution
There is a lot of concern about diet and nutrition for these population, like Newborns, children, pregnant, sensitive to Glycine populations. Better consult to your doctor if you would like to intake Glycine.
Related Research
1. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients–a preliminary 10-week open-label study]. [Psychiatr Pol. 2013 Jul-Aug] Author: Strzelecki D, Kropiwnicki P, Rabe-Jabłońska J.
2. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. [Clin Nutr. 2014 Jun] Author: Ham DJ, Murphy KT, Chee A, Lynch GS, Koopman R.
3. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study]. [Psychiatr Pol. 2011 Nov-Dec] Author: Strzelecki D, Rabe-Jabłońska J.
4. Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. [Pharmacol Rep. 2010 Mar-Apr] Author: Socała K, Nieoczym D, Rundfeldt C, Wlaź P.